221 related articles for article (PubMed ID: 31488093)
1. Association of LncRNA MEG3 polymorphisms with efficacy of neoadjuvant chemotherapy in breast cancer.
Bayarmaa B; Wu Z; Peng J; Wang Y; Xu S; Yan T; Yin W; Lu J; Zhou L
BMC Cancer; 2019 Sep; 19(1):877. PubMed ID: 31488093
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
3. Association analyses of a genetic variant in long non-coding RNA MEG3 with breast cancer susceptibility and serum MEG3 expression level in the Egyptian population.
Ali MA; Shaker OG; Alazrak M; AbdelHafez MN; Khalefa AA; Hemeda NF; Abdelmoktader A; Ahmed FA
Cancer Biomark; 2020; 28(1):49-63. PubMed ID: 32176630
[TBL] [Abstract][Full Text] [Related]
4. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
Resende U; Cabello C; Ramalho SOB; Zeferino LC
BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
[TBL] [Abstract][Full Text] [Related]
5. Programmed death-ligand 1 single nucleotide polymorphism affects breast cancer chemosensitivity and adverse events in the neoadjuvant setting.
Lu J; Wu Z; Peng J; Xu S; Zhou L; Lin Y; Wang Y; Yin W; Lu J
Int J Biol Markers; 2020 Sep; 35(3):90-101. PubMed ID: 33073683
[TBL] [Abstract][Full Text] [Related]
6. Decreased expression of long non-coding RNA MEG3 acts as a potential predictor biomarker in progression and poor prognosis of osteosarcoma.
Tian ZZ; Guo XJ; Zhao YM; Fang Y
Int J Clin Exp Pathol; 2015; 8(11):15138-42. PubMed ID: 26823857
[TBL] [Abstract][Full Text] [Related]
7. S4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer.
Shao X; Cai J; Zheng Y; Wang J; Feng J; Huang Y; Shi L; Chen Z; Guo Y; Wang X
Int J Clin Exp Pathol; 2015; 8(5):5309-17. PubMed ID: 26191232
[TBL] [Abstract][Full Text] [Related]
8. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.
Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J
J Cell Mol Med; 2020 Mar; 24(5):2993-3021. PubMed ID: 31989747
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Lluch A; Tjulandin S; Zambetti M; Moliterni A; Vazquez F; Byakhov MJ; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Magazzù D; Heinzmann D; Steinseifer J; Valagussa P; Baselga J
Lancet Oncol; 2014 May; 15(6):640-7. PubMed ID: 24657003
[TBL] [Abstract][Full Text] [Related]
11. Maternally expressed gene 3 (MEG3): A tumor suppressor long non coding RNA.
Ghafouri-Fard S; Taheri M
Biomed Pharmacother; 2019 Oct; 118():109129. PubMed ID: 31326791
[TBL] [Abstract][Full Text] [Related]
12. LncRNA MEG3 rs3087918 was associated with a decreased breast cancer risk in a Chinese population: a case-control study.
Zheng Y; Wang M; Wang S; Xu P; Deng Y; Lin S; Li N; Liu K; Zhu Y; Zhai Z; Wu Y; Dai Z; Zhu G
BMC Cancer; 2020 Jul; 20(1):659. PubMed ID: 32669097
[TBL] [Abstract][Full Text] [Related]
13. Relationship between MEG3 gene polymorphism and risk of gastric cancer in Chinese population with high incidence of gastric cancer.
Kong X; Yang S; Liu C; Tang H; Chen Y; Zhang X; Zhou Y; Liang G
Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33119060
[TBL] [Abstract][Full Text] [Related]
14. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
[TBL] [Abstract][Full Text] [Related]
15. OCA2 rs4778137 polymorphism predicts survival of breast cancer patients receiving neoadjuvant chemotherapy.
Li XP; Lan JY; Liu DQ; Zhou H; Qian MM; Wang WW; Yang M
Gene; 2018 Apr; 651():161-165. PubMed ID: 29409738
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma.
Fan Y; Jiang Y; Zhou X; Chen Q; Huang Z; Xu Y; Gong L; Yu H; Yang H; Liu J; Lei T; Zhao Q; Mao W
Oncotarget; 2016 Aug; 7(31):50624-50634. PubMed ID: 27244882
[TBL] [Abstract][Full Text] [Related]
17. Associations between polymorphisms of long non-coding RNA MEG3 and risk of colorectal cancer in Chinese.
Cao X; Zhuang S; Hu Y; Xi L; Deng L; Sheng H; Shen W
Oncotarget; 2016 Apr; 7(14):19054-9. PubMed ID: 26934323
[TBL] [Abstract][Full Text] [Related]
18. Circulating HOTAIR expression predicts the clinical response to neoadjuvant chemotherapy in patients with breast cancer.
Lu R; Zhang J; Zhang W; Huang Y; Wang N; Zhang Q; Qu S
Cancer Biomark; 2018; 22(2):249-256. PubMed ID: 29630518
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
[TBL] [Abstract][Full Text] [Related]
20. Predictive and prognostic value of ZEB1 protein expression in breast cancer patients with neoadjuvant chemotherapy.
Wu Z; Zhang L; Xu S; Lin Y; Yin W; Lu J; Sha R; Sheng X; Zhou L; Lu J
Cancer Cell Int; 2019; 19():78. PubMed ID: 30976202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
